Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

PCI Biotech Holding A stock price, quote, forecast and news

PCIB.OL
NO0010405640
A0Q2FS

Price

1.77 NOK
Today +/-
+0.00 NOK
Today %
+0.79 %
P

PCI Biotech Holding A stock price

NOK
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the PCI Biotech Holding A stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the PCI Biotech Holding A stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the PCI Biotech Holding A stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze PCI Biotech Holding A's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

PCI Biotech Holding A Stock Price History

DatePCI Biotech Holding A Price
9/11/20241.77 NOK
9/10/20241.76 NOK
9/9/20241.80 NOK
9/6/20241.85 NOK
9/5/20241.85 NOK
9/4/20241.85 NOK
9/3/20241.82 NOK
9/2/20241.99 NOK
8/30/20241.85 NOK
8/29/20241.80 NOK
8/28/20241.80 NOK
8/27/20241.68 NOK
8/26/20241.72 NOK
8/23/20241.76 NOK
8/22/20241.75 NOK
8/21/20241.80 NOK
8/20/20241.80 NOK
8/19/20241.79 NOK
8/16/20241.73 NOK
8/15/20241.73 NOK

PCI Biotech Holding A Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PCI Biotech Holding A, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PCI Biotech Holding A from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PCI Biotech Holding A’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PCI Biotech Holding A. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PCI Biotech Holding A’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PCI Biotech Holding A’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PCI Biotech Holding A’s growth potential.

PCI Biotech Holding A Revenue, EBIT and net profit per share

DatePCI Biotech Holding A RevenuePCI Biotech Holding A EBITPCI Biotech Holding A Net Income
2024e7.27 M NOK-88.81 M NOK-83.08 M NOK
20232.99 M NOK-22.24 M NOK-20.32 M NOK
20224.75 M NOK-56.45 M NOK-55.1 M NOK
20216.27 M NOK-86.03 M NOK-88.39 M NOK
20207.37 M NOK-82.12 M NOK-72.24 M NOK
20199.39 M NOK-88.8 M NOK-88.75 M NOK
20189.59 M NOK-44.52 M NOK-34.78 M NOK
201710.25 M NOK-43.43 M NOK-42.84 M NOK
201610.48 M NOK-33.03 M NOK-32.18 M NOK
201510.47 M NOK-32.63 M NOK-31.92 M NOK
20147.3 M NOK-36.47 M NOK-35.84 M NOK
20136.68 M NOK-29.33 M NOK-27.61 M NOK
20126.77 M NOK-27.35 M NOK-25.26 M NOK
20117.42 M NOK-17.08 M NOK-13.75 M NOK
201010.44 M NOK-16.24 M NOK-13.94 M NOK
20098.61 M NOK-17.69 M NOK-15.02 M NOK
20087.37 M NOK-12.14 M NOK-11.38 M NOK
20070 NOK0 NOK0 NOK

PCI Biotech Holding A Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M NOK)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M NOK)EBIT (M NOK)EBIT MARGIN (%)NET INCOME (M NOK)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200720082009201020112012201320142015201620172018201920202021202220232024e
0781076671010109976427
--14.2925.00-30.00-14.29-16.6742.86---10.00--22.22-14.29-33.33-50.00250.00
--------------100.00100.00--
000000000000006400
0-12-17-16-17-27-29-36-32-33-43-44-88-82-86-56-22-88
--171.43-212.50-160.00-242.86-450.00-483.33-514.29-320.00-330.00-430.00-488.89-977.78-1,171.43-1,433.33-1,400.00-1,100.00-1,257.14
0-11-15-13-13-25-27-35-31-32-42-34-88-72-88-55-20-83
--36.36-13.33-92.318.0029.63-11.433.2331.25-19.05158.82-18.1822.22-37.50-63.64315.00
10.177.5710.1711.0812.8512.8512.912.9520.1116.0526.2327.837.2337.2937.3337.3337.330
------------------
Details

Keystats

ⓘ

Revenue and Growth

The PCI Biotech Holding A Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PCI Biotech Holding A is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M NOK)RECEIVABLES (M NOK)OTHER REC. (M NOK)INVENTORIES (M NOK)OTHER CURRENT LIAB. (M NOK)CURRENT ASSETS (M NOK)TANGIBLE ASSETS (M NOK)LONG-T. INVEST. (M NOK)LONG-T. REC. (M NOK)INTANGIBLE ASSETS (k NOK)GOODWILL (M NOK)OTHER NON-CURRENT ASSETS (M NOK)NON-CURRENT ASSETS (M NOK)TOTAL ASSETS (M NOK)LIABILITIESCOMMON STOCK (M NOK)ADDITIONAL PAID-IN CAPITAL (M NOK)RETAINED EARNINGS (M NOK)OTHER EQUITY (M NOK)UNREAL. GAINS/LOSSES (M NOK)EQUITY (M NOK)LIABILITIES (M NOK)PROVISIONS (M NOK)OTHER SHORT-TERM LIAB. (M NOK)SHORT-TERM DEBTS (M NOK)LONG-TERM DEBT PORTION (k NOK)SHORT-TERM REC. (M NOK)LONG-T. LIAB. (M NOK)DEFERRED TAXES (M NOK)OTHER LIAB. (M NOK)LONG-T. LIABILITIES (M NOK)DEBT (M NOK)TOTAL CAPITAL (M NOK)
20072008200920102011201220132014201520162017201820192020202120222023
                                 
150.135.8110.895.173.146.615.7549.251450.79349.33261.1187.97116.1256.641.18
00.30.40.10.40.3007.1400000002.57
03.95.13.54.64.86.14.61007.637.7114.6513.1612.200
00000000000000000
0000000000000000-0
154.341.3114.4100.178.252.720.3756.391458.41357.04275.75201.13128.3256.643.75
00.10.20.10000.010.010.010.020.026.287.997.660.720.3
00000000000000000
000000000000005.16.160
0100000000000000000
00000000000000000
00000000000000000
00.20.20.10000.010.010.010.020.026.287.9912.766.880.3
154.541.5114.5100.178.252.720.3856.414.0158.44357.06282.03209.12141.0863.4844.05
                                 
116.216.223232323.223.1844.744.774.96111.49111.8111.98111.98111.981.12
00.490167.5168.476.576.776.73120.68120.68157.15449.45450.33450.46450.46037.92
0880-85.1-98.9-124.1-56.5-90.8-121.09-152.29-190.27-220.99-307.3-373.2-448.65-54.580
0-55.4-71.20094.300-00-00-00-000
00000000000000000
149.235105.492.569.743.49.1144.2813.0941.84339.95254.83189.24113.7957.439.04
02.72.622.224.12.593.372.081.51.898.65.193.750.50.71
0000000000013.1310.6911.8814.223.373.07
02.23.2434.43.87.528.747.2313.091.984.692.112.321.440.87
00.30.70.60.71.31.41.16000000000
000000000000657673629443319
05.26.56.65.97.79.311.2712.129.3114.5816.9924.6319.8520.915.754.97
0000000000000.5401.280.330
00000000000000000
0002.51.80.80.10002.010.112.040.03000.03
0002.51.80.80.10002.010.112.580.031.280.330.03
05.26.59.17.78.59.411.2712.129.3116.5917.127.219.8822.196.085.01
154.441.5114.5100.278.252.820.3856.422.458.44357.06282.03209.12135.9863.4844.05
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of PCI Biotech Holding A provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand PCI Biotech Holding A's financial health and stability.

Assets

PCI Biotech Holding A's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that PCI Biotech Holding A must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of PCI Biotech Holding A after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into PCI Biotech Holding A's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M NOK)DEPRECIATION (M NOK)DEFERRED TAXES (M NOK)CHANGES IN WORKING CAPITAL (M NOK)NON-CASH ITEM (M NOK)PAID INTEREST (M NOK)PAID TAXES (M NOK)NET CASH FLOW FROM OPERATING ACTIVITIES (M NOK)CAPITAL EXPENDITURES (M NOK)CASH FLOW FROM INVESTING ACTIVITIES (M NOK)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M NOK)INTEREST INCOME AND EXPENSES (M NOK)NET DEBT CHANGE (M NOK)NET CHANGE IN EQUITY (M NOK)CASH FLOW FROM FINANCING ACTIVITIES (M NOK)CASH FLOW FROM OTHER FINANCING ACTIVITIES (NOK)TOTAL DIVIDENDS PAID (M NOK)NET CHANGE IN CASH FLOW (M NOK)FREE CASH FLOW (M NOK)SHARE-BASED COMPENSATION (M NOK)
20072008200920102011201220132014201520162017201820192020202120222023
0-11-15-13-13-25-27-35-31-32-42-34-88-72-88-55-20
00000000000002260
00000000000000000
01-22-6-1-12-2-4801-52-82
00010201104-52-215-12
00000000000000000
00000000000000000
0-9-16-10-19-24-28-31-32-35-30-40-83-77-68-59-15
000000000000-5-3000
002232100000-3-3000
00223210000010000
00000000000000000
00000000000000000
06009000006507132810000
05508300006506632800000
--4.00--6.00-------4.00------
00000000000000000
046-1474-15-22-26-3033-3536298-88-73-71-59-15
0-9.53-16.95-10.59-19.05-24.35-28.59-31.67-32.84-35.69-30.62-40.17-88.88-81.31-68.65-59.04-15.07
00000000000000000

PCI Biotech Holding A stock margins

The PCI Biotech Holding A margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PCI Biotech Holding A. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PCI Biotech Holding A.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PCI Biotech Holding A's sales revenue. A higher gross margin percentage indicates that the PCI Biotech Holding A retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PCI Biotech Holding A's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PCI Biotech Holding A's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PCI Biotech Holding A's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PCI Biotech Holding A. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PCI Biotech Holding A's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PCI Biotech Holding A Margin History

PCI Biotech Holding A Gross marginPCI Biotech Holding A Profit marginPCI Biotech Holding A EBIT marginPCI Biotech Holding A Profit margin
2024e100 %-1,221.14 %-1,142.36 %
2023100 %-743.85 %-679.43 %
2022100 %-1,188.36 %-1,159.89 %
202199.95 %-1,371.42 %-1,409.07 %
2020100 %-1,114.56 %-980.44 %
2019100 %-945.52 %-944.91 %
2018100 %-464.47 %-362.86 %
2017100 %-423.72 %-417.96 %
2016100 %-315.29 %-307.25 %
2015100 %-311.73 %-304.98 %
2014100 %-499.82 %-491.16 %
2013100 %-439.07 %-413.32 %
2012100 %-403.99 %-373.12 %
2011100 %-230.19 %-185.31 %
2010100 %-155.56 %-133.52 %
2009100 %-205.46 %-174.45 %
2008100 %-164.72 %-154.41 %
2007100 %0 %0 %

PCI Biotech Holding A Stock Sales Revenue, EBIT, Earnings per Share

The PCI Biotech Holding A earnings per share therefore indicates how much revenue PCI Biotech Holding A has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PCI Biotech Holding A earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PCI Biotech Holding A's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PCI Biotech Holding A’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PCI Biotech Holding A's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PCI Biotech Holding A Revenue, EBIT and net profit per share

DatePCI Biotech Holding A Sales per SharePCI Biotech Holding A EBIT per sharePCI Biotech Holding A Earnings per Share
2024e0.19 NOK0 NOK-2.23 NOK
20230.08 NOK-0.6 NOK-0.54 NOK
20220.13 NOK-1.51 NOK-1.48 NOK
20210.17 NOK-2.3 NOK-2.37 NOK
20200.2 NOK-2.2 NOK-1.94 NOK
20190.25 NOK-2.39 NOK-2.38 NOK
20180.34 NOK-1.6 NOK-1.25 NOK
20170.39 NOK-1.66 NOK-1.63 NOK
20160.65 NOK-2.06 NOK-2.01 NOK
20150.52 NOK-1.62 NOK-1.59 NOK
20140.56 NOK-2.82 NOK-2.77 NOK
20130.52 NOK-2.27 NOK-2.14 NOK
20120.53 NOK-2.13 NOK-1.97 NOK
20110.58 NOK-1.33 NOK-1.07 NOK
20100.94 NOK-1.47 NOK-1.26 NOK
20090.85 NOK-1.74 NOK-1.48 NOK
20080.97 NOK-1.6 NOK-1.5 NOK
20070 NOK0 NOK0 NOK

PCI Biotech Holding A business model

PCI Biotech Holding ASA is a biopharmaceutical company based in Norway that focuses on the clinical development of drugs based on the so-called "Photochemical Internalization" (PCI) technology. The company was founded in 2000 as a spin-off from the Norwegian Cancer Society. The PCI technology, which is based on the use of light and chemicals to transport drugs into cells, was developed by Norwegian researchers in the 1990s. Since then, PCI Biotech has been working in collaboration with various research institutions and pharmaceutical companies to optimize this technology and advance its application in medicine. PCI Biotech's business model is based on providing its PCI technology and expertise to partners in research and industry. At the same time, the company also conducts its own clinical research on drugs based on the PCI technology. The goal is to develop drugs that are effective in various forms of cancer and other serious diseases. PCI Biotech is divided into two main divisions: the project department, which works on the development of its own drugs, and the service department, which licenses its PCI technology to third parties. One significant product of the project department is the drug "Amphinex," which is used in the treatment of pancreatic cancer. Amphinex is administered to patients in combination with chemotherapy to enhance the effectiveness of the chemotherapy. Amphinex activates the PCI technology in cancer cells, thereby facilitating the penetration of the chemotherapeutic agent into the cells. Other projects in the company's pipeline include drugs for the treatment of prostate cancer and skin cancer, as well as targeted destruction of tumor cells in the brain. The service department offers various solutions for the academic and industrial sectors. The PCI technology can be used in the development of drugs for the treatment of other diseases, such as viral infections or inflammatory diseases. Furthermore, the PCI technology can also be utilized in imaging or diagnostics. Overall, PCI Biotech is a company specialized in the development of innovative drugs. By using the PCI technology, drugs can be delivered more specifically and effectively into cells, opening up new possibilities in cancer treatment and other areas of medicine. PCI Biotech has become a significant player in clinical research in recent years and works closely with other research institutions and pharmaceutical companies to optimize their technology and explore new application areas. PCI Biotech Holding A is one of the most popular companies on Eulerpool.com.

PCI Biotech Holding A SWOT Analysis

Strengths

1. Strong Intellectual Property (IP) portfolio: PCI Biotech Holding ASA possesses a robust IP portfolio, which includes patents covering its drug delivery technology called Photochemical Internalization (PCI). This gives the company a competitive advantage in the market.

2. Strategic collaborations: The company has established partnerships with renowned pharmaceutical companies, enabling access to valuable resources, expertise, and potential funding. This strengthens its position in the industry and enhances its growth prospects.

3. Innovative technology platform: PCI Biotech's PCI technology platform has shown promising results in preclinical and clinical studies, demonstrating its potential in enhancing the efficacy of existing drugs and enabling the development of novel treatments.

Weaknesses

1. Limited product portfolio: The company currently has a limited number of products in its pipeline, which increases the risk associated with relying on the success of a small number of candidates for future revenue generation.

2. Dependency on partnerships: While partnerships provide benefits, PCI Biotech's dependence on collaborations for resources and funding may limit its control over decision-making and potentially restrict its growth opportunities.

3. Early-stage development: Most of the company's products are still in the early stages of development and are subject to uncertainties and risks associated with clinical trials and regulatory approvals.

Opportunities

1. Growing demand for targeted therapies: The increasing focus on personalized medicine and targeted therapies presents an opportunity for PCI Biotech's innovative drug delivery technology, which can enhance the efficacy of existing drugs and enable the development of new targeted treatments.

2. Expansion into new indications: The company's PCI technology has the potential to be applied to various diseases and indications beyond its current pipeline. Exploring and expanding into new therapeutic areas can widen the market potential and revenue streams.

3. Emerging markets: The company can explore opportunities in emerging markets, where there is a growing demand for advanced medical technologies, including innovative drug delivery systems. This can contribute to revenue growth and market expansion.

Threats

1. Intense competition: The biotechnology and pharmaceutical industries are highly competitive, with numerous companies developing similar technologies and treatments. PCI Biotech faces the risk of competitors offering alternative solutions or gaining a competitive advantage.

2. Regulatory challenges: The company's products are subject to rigorous regulatory approval processes, which can be time-consuming and expensive. Compliance with evolving regulations and potential delays in approvals pose threats to the company's development timelines and financials.

3. Market volatility and economic factors: Fluctuations in financial markets, currency exchange rates, economic recessions, and changes in healthcare reimbursement policies can impact the company's funding, pricing, and market acceptance of its products.

PCI Biotech Holding A Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

PCI Biotech Holding A historical P/E ratio, EBIT, and P/S ratio.

PCI Biotech Holding A shares outstanding

The number of shares was PCI Biotech Holding A in 2023 — This indicates how many shares 37.326 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PCI Biotech Holding A earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PCI Biotech Holding A's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PCI Biotech Holding A’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PCI Biotech Holding A's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for PCI Biotech Holding A.

PCI Biotech Holding A latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2013-0.42 NOK-0.42 NOK (-0.88 %)2013 Q2
12/31/2012-0.58 NOK-0.65 NOK (-12.48 %)2012 Q4
6/30/2012-0.45 NOK-0.29 NOK (35.08 %)2012 Q2
3/31/2012-0.29 NOK-0.43 NOK (-50.18 %)2012 Q1
3/31/2011-0.34 NOK-0.25 NOK (26.48 %)2011 Q1
12/31/2010-0.33 NOK-0.32 NOK (1.96 %)2010 Q4
6/30/2010-0.57 NOK-0.66 NOK (-15.96 %)2010 Q2
12/31/2008-0.29 NOK-0.49 NOK (-65.93 %)2008 Q4
9/30/2008-0.3 NOK-0.25 NOK (14.79 %)2008 Q3
6/30/2008-1.55 NOK-0.05 NOK (96.56 %)2008 Q2
1

PCI Biotech Holding A list of shareholders

%
Name
Stocks
Change
Date
4.30205 % MP Pensjon1,605,801-200,0001/12/2024
2.89986 % Radforsk Investeringsstiftelse1,082,415012/31/2022
10.47635 % FONDSAVANSE AS3,910,44301/12/2024
1.71728 % Gresslien (Odd Roar)641,000-247,8001/12/2024
1.40115 % Zhang (Lin Hui)523,000523,0001/12/2024
1.33953 % RAVI INVESTERING AS500,00001/12/2024
1.15303 % Nordnet Livsforsikring AS430,385-56,1661/12/2024
1.07163 % Ricove AS400,000400,0001/12/2024
1.03144 % Jandersen Kapital AS385,000-15,0001/12/2024
1.02967 % Forenede Forvaltning AS384,338-8501/12/2024
1
2
3

Most common questions regarding PCI Biotech Holding A

What values and corporate philosophy does PCI Biotech Holding A represent?

PCI Biotech Holding ASA is a leading biotechnology company that upholds strong values and a well-defined corporate philosophy. The company envisions transforming patient care through innovative therapeutic solutions. PCI Biotech Holding ASA focuses on developing and commercializing its proprietary drug delivery technologies for the treatment of serious diseases, with a particular emphasis on cancer. With a commitment to scientific excellence, ethical conduct, and patient-centric approach, the company aims to create value for patients, healthcare providers, and shareholders alike. Embracing continuous innovation and collaboration, PCI Biotech Holding ASA aims to make a positive impact on healthcare outcomes worldwide.

In which countries and regions is PCI Biotech Holding A primarily present?

PCI Biotech Holding ASA is primarily present in Norway.

What significant milestones has the company PCI Biotech Holding A achieved?

PCI Biotech Holding ASA has achieved several significant milestones. The company successfully completed a Phase I clinical trial for its lead product, Amphinex, which showed promising results in treating bile duct cancer. Additionally, PCI Biotech Holding ASA secured a collaboration agreement with a major pharmaceutical company to explore the potential of Amphinex in combination with their immunotherapy drug. The company also received Orphan Drug Designation in Europe for the treatment of bile duct cancer using Amphinex. These achievements demonstrate PCI Biotech Holding ASA's dedication to advancing cancer treatments and highlight the potential of its innovative technology.

What is the history and background of the company PCI Biotech Holding A?

PCI Biotech Holding ASA is a Norwegian biopharmaceutical company established in 2000. With a focus on developing innovative cancer treatments, PCI Biotech Holding ASA has built a strong history and background in the field. The company specializes in developing photosensitizers, light sources, and drug delivery technologies for cancer therapy. PCI Biotech Holding ASA is known for its expertise in photochemical internalization (PCI), a technology that enhances the effect of drugs by releasing them inside cells. This innovative approach holds great potential for improving cancer treatment outcomes. Over the years, PCI Biotech Holding ASA has garnered recognition and formed strong partnerships within the healthcare industry, solidifying its position as a leader in the field of cancer therapeutics.

Who are the main competitors of PCI Biotech Holding A in the market?

The main competitors of PCI Biotech Holding ASA in the market are other biotech companies and pharmaceutical companies that operate in the same field of research and development. Some notable competitors include AstraZeneca, Novartis, Pfizer, and Gilead Sciences. These companies, like PCI Biotech Holding ASA, are engaged in the development of innovative therapies, drugs, and treatments aimed at addressing various diseases and conditions. PCI Biotech Holding ASA strives to differentiate itself through its unique approaches and technology platforms to gain a competitive edge in the market.

In which industries is PCI Biotech Holding A primarily active?

PCI Biotech Holding ASA is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of PCI Biotech Holding A?

The business model of PCI Biotech Holding ASA is focused on the development and commercialization of innovative therapies targeting cancer through its proprietary platform technology, known as Photochemical Internalization (PCI). PCI Biotech aims to improve the efficacy of existing treatments by enhancing the delivery of drugs to cancer cells, thus increasing the potential for successful outcomes. By leveraging its expertise in drug delivery and partnering with pharmaceutical companies, PCI Biotech aims to bring novel and effective therapeutics to market, addressing unmet medical needs and ultimately benefiting patients worldwide.

What is the P/E ratio of PCI Biotech Holding A 2024?

The PCI Biotech Holding A P/E ratio is -0.8.

What is the P/S ratio of PCI Biotech Holding A 2024?

The PCI Biotech Holding A P/S ratio is 9.09.

What is the AlleAktien quality score of PCI Biotech Holding A?

The AlleAktien quality score for PCI Biotech Holding A is 3/10.

What is the revenue of PCI Biotech Holding A 2024?

The expected PCI Biotech Holding A revenue is 7.27 M NOK.

How high is the profit of PCI Biotech Holding A 2024?

The expected PCI Biotech Holding A profit is -83.08 M NOK.

What is the business model of PCI Biotech Holding A

PCI Biotech Holding ASA is a Norwegian biotechnology company specializing in the development of drugs for the treatment of severe diseases. The company was founded in 2000 and specializes in the development of drugs based on phototherapy. The company operates in two main business areas: PCI (Photochemical Internal Therapy) and fimaNAc (nanoparticle-based mRNA delivery). PCI (Photochemical Internal Therapy) is a proprietary technology platform for targeted release of drugs into cells. The PCI technology is based on a combination of light-sensitive drugs that target specific cells or tissues, and targeted light that triggers the release of the drugs. The PCI technology has the potential to increase the efficacy of existing drugs and create new therapies and treatment options for a variety of diseases. In the field of fimaNAc (nanoparticle-based mRNA delivery), PCI Biotech has developed a technology platform focusing on the use of nanoparticles for targeted delivery of mRNA drugs. The fimaNAc technology combines the advantages of lipid and polymer nanoparticles, allowing the transport of mRNA molecules into cells. fimaNAc is a revolutionary technology that has the potential to increase the efficacy of mRNA-based drugs and create new therapies for a variety of diseases. PCI Biotech has successfully conducted clinical trials with promising results in both business areas. The company has entered into several partnerships with leading biotechnology and pharmaceutical companies to utilize its technology platforms and further develop its drug candidates. In addition, the company works closely with academic and clinical partners to identify and develop new therapy options for patients. PCI Biotech's key product is Amphinex, which is currently under investigation in advanced clinical trials for the treatment of pancreatic cancer. Amphinex is used in combination with the chemotherapy drug Gemcitabine and has the potential to significantly improve the response to chemotherapy. Another promising product from PCI Biotech is a collaborative development alliance with AstraZeneca in the field of fimaNAc technology for the treatment of cancer. The alliance aims to utilize PCI Biotech's fimaNAc technology for efficient delivery of mRNA drugs that influence the production of proteins crucial for the growth of cancer cells. Overall, PCI Biotech has developed a promising technology platform that has the potential to revolutionize the treatment of serious diseases such as cancer. The company has leveraged collaborations with leading biotechnology and pharmaceutical companies to utilize its technology platforms and further develop its drug candidates. With a promising product pipeline and strong financial position, PCI Biotech is positioning itself as a leading company in the biotechnology industry.

What is the PCI Biotech Holding A dividend?

PCI Biotech Holding A pays a dividend of 0 NOK distributed over payouts per year.

How often does PCI Biotech Holding A pay dividends?

The dividend cannot currently be calculated for PCI Biotech Holding A or the company does not pay out a dividend.

What is the PCI Biotech Holding A ISIN?

The ISIN of PCI Biotech Holding A is NO0010405640.

What is the PCI Biotech Holding A WKN?

The WKN of PCI Biotech Holding A is A0Q2FS.

What is the PCI Biotech Holding A ticker?

The ticker of PCI Biotech Holding A is PCIB.OL.

How much dividend does PCI Biotech Holding A pay?

Over the past 12 months, PCI Biotech Holding A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PCI Biotech Holding A is expected to pay a dividend of 0 NOK.

What is the dividend yield of PCI Biotech Holding A?

The current dividend yield of PCI Biotech Holding A is .

When does PCI Biotech Holding A pay dividends?

PCI Biotech Holding A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PCI Biotech Holding A?

PCI Biotech Holding A paid dividends every year for the past 0 years.

What is the dividend of PCI Biotech Holding A?

For the upcoming 12 months, dividends amounting to 0 NOK are expected. This corresponds to a dividend yield of 0 %.

In which sector is PCI Biotech Holding A located?

PCI Biotech Holding A is assigned to the 'Health' sector.

Wann musste ich die Aktien von PCI Biotech Holding A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PCI Biotech Holding A from 9/13/2024 amounting to 0 NOK, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did PCI Biotech Holding A pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of PCI Biotech Holding A in the year 2023?

In the year 2023, PCI Biotech Holding A distributed 0 NOK as dividends.

In which currency does PCI Biotech Holding A pay out the dividend?

The dividends of PCI Biotech Holding A are distributed in NOK.

All fundamentals about PCI Biotech Holding A

Our stock analysis for PCI Biotech Holding A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PCI Biotech Holding A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.